ENTITY
Astellas Pharma

Astellas Pharma (4503 JP)

228
Analysis
Health Care • Japan
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia
more
•04 Mar 2017 11:12

The Week That Was in NorthAsia@Smartkarma - Jelly Drinks, Dental Implants, & Tires

This is the inaugural report of "The Week That Was in North Asia@Smartkarma. This is a collaborative report among Travis Lundy, Mio Kato, CFA,...

Logo
446 Views
Share
•27 Feb 2017 14:28

AI & Machine Learning Disrupting The Healthcare Industry

In the omnipresence of machine learning, one of the most impacted segments is healthcare. Not only is AI in healthcare at the forefront of a...

Logo
786 Views
Share
bullish•Sumitomo Pharma
•21 Apr 2026 10:02

Sumitomo Pharma (4506 JP): Placement Is In Line With “Boost 2028” Plan, R&D in Focus

Sumitomo Pharma announced the placement price to be ÂĄ1990 per share. Net proceeds of ÂĄ111.6B yen is expected to be used for R&D in oncology (~...

Logo
270 Views
Share
•30 Jan 2017 13:50

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...

•21 Apr 2026 06:15

Mabwell (Shanghai) Bioscience IPO: Aiming for Next Level of Growth Riding on ADC Pipeline

Mabwell seeks to raise ~$185M via HK IPO, which consists of 47M H shares. Offer price range is HK$27.64–30.71 per share. Subscriptions will close...

Logo
247 Views
Share
x